AbTis Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

AbTis General Information

Description

Operator of a biotechnology company intended to offer antibody-drug conjugation technology and solubilization of drugs. The company's technology is designed to enhance the safety and efficacy of the current antibody-drug conjugates, also applicable to native antibodies, commercial antibodies, or novel antibodies under development as it requires no mutation or engineering to the antibody itself, enabling medical professionals to get access to antibody-drug conjugate.

Contact Information

Website
www.abtis.co.kr
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Venture Valley 2 A-815
  • Sanup-ro 156, 142-10 Kwonsun-gu
  • Suwon, Gyeonggi 16648
  • South Korea
+82
Primary Industry
Biotechnology
Parent Company
Dong-A ST Co
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Venture Valley 2 A-815
  • Sanup-ro 156, 142-10 Kwonsun-gu
  • Suwon, Gyeonggi 16648
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbTis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 20-Dec-2023 Completed Generating Revenue
5. Accelerator/Incubator 03-Aug-2023 Completed Pre-Clinical Trials
4. Later Stage VC 06-Mar-2023 Completed Pre-Clinical Trials
3. Later Stage VC (Series B) 31-Jan-2021 Completed Startup
2. Early Stage VC (Series A) 12-Jun-2018 $4.64M $5.14M Completed Startup
1. Seed Round 01-Jan-2017 $500K $500K Completed Startup
To view AbTis’s complete valuation and funding history, request access »

AbTis Patents

  • 62

    Total Documents Applications and Grants

  • Total Patents Families

  • 31

    Granted

  • 23

    Pending

  • Expiring in next 12 mo

AbTis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025230314-A1 Compound comprising fc-binding unit, and conjugate prepared using same Pending 30-Apr-2024
WO-2025053366-A1 Compound comprising fc-binding unit, and conjugate prepared using same Inactive 07-Sep-2023
AU-2023371751-A1 Antibody-drug conjugate comprising anti-claudin-18.2 antibody, and therapeutic use thereof for cancer Pending 01-Nov-2022
EP-4613291-A1 Antibody-drug conjugate comprising anti-claudin-18.2 antibody, and therapeutic use thereof for cancer Pending 01-Nov-2022
US-20260151501-A1 Antibody-drug conjugate comprising anti-claudin-18.2 antibody, and therapeutic use thereof for cancer Pending 01-Nov-2022 A61K47/68031
To view AbTis’s complete patent history, request access »

AbTis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbTis Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
AJU IB Investment Venture Capital Minority
CKD Venture Capital Corporate Venture Capital Minority
JX Partners Venture Capital Minority
K2 Investment Partners Venture Capital Minority
KDB Capital PE/Buyout Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

AbTis FAQs

  • When was AbTis founded?

    AbTis was founded in 2016.

  • Where is AbTis headquartered?

    AbTis is headquartered in Suwon, South Korea.

  • What is the size of AbTis?

    AbTis has 20 total employees.

  • What industry is AbTis in?

    AbTis’s primary industry is Biotechnology.

  • Is AbTis a private or public company?

    AbTis is a Private company.

  • What is AbTis’s current revenue?

    The current revenue for AbTis is .

  • How much funding has AbTis raised over time?

    AbTis has raised $18.8M.

  • Who are AbTis’s investors?

    AJU IB Investment, CKD Venture Capital, JX Partners, K2 Investment Partners, and KDB Capital are 5 of 13 investors who have invested in AbTis.

  • When was AbTis acquired?

    AbTis was acquired on 20-Dec-2023.

  • Who acquired AbTis?

    AbTis was acquired by Dong-A ST Co.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process